The evolution of the therapeutic approach to membranous nephropathy.

  title={The evolution of the therapeutic approach to membranous nephropathy.},
  author={Claudio Ponticelli and Passerini Patrizia and Lucia Del Vecchio and Francesco Locatelli},
  journal={Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association},
  • C. Ponticelli, P. Patrizia, +1 author F. Locatelli
  • Published 24 March 2020
  • Medicine
  • Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Primary membranous nephropathy (MN) is a frequent cause of nephrotic syndrome (NS) in adults. In untreated patients, the outcome is variable, with one-third of the patients entering remission while the remaining ones show persisting proteinuria or progression to end-stage renal disease. Randomized clinical trials reported the efficacy of a 6-month regimen alternating intravenous and oral glucocorticoids with an alkylating agent every other month. The potential side effects of this regimen were… Expand
Rituximab in Membranous Nephropathy
An overview of the current literature is provided and questions remain about how to best use rituximab, including the optimal dosing regimen, a potential need for maintenance therapy, and assessment of long-term safety and efficacy outcomes. Expand
Retrospective analysis of Tripterygium wilfordii polyglycoside combined with angiotensin receptor blockers for the treatment of primary membranous nephropathy with sub-nephrotic proteinuria
Tripterygium wilfordii polyglycoside may be a promising treatment for PMN patients with sub-nephrotic proteinuria, whether anti-PLA2R antibody is positive or negative. Expand


A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy.
Untreated IMN with nephrotic syndrome is associated with a high risk for deterioration of renal function, and a 6-mo regimen of cyclophosphamide and steroids induces remissions in a high proportion, arrests progression of renal insufficiency, and improves quality of life. Expand
Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial.
Tacrolimus is a very useful therapeutic option for patients with membranous nephropathy and preserved renal function and the majority of patients experienced remission with a significant reduction in the risk for deteriorating renal function. Expand
Rituximab therapy in idiopathic membranous nephropathy: a 2-year study.
Four doses of RTX resulted in more effective B cell depletion, but proteinuria reduction was similar to RTX at 1 g every 2 weeks, which could potentially result in undertreatment. Expand
Mycophenolate mofetil monotherapy in membranous nephropathy: a 1-year randomized controlled trial.
  • B. Dussol, S. Morange, +14 authors Y. Berland
  • Medicine
  • American journal of kidney diseases : the official journal of the National Kidney Foundation
  • 2008
A 12-month regimen of MMF did not decrease mean proteinuria over creatinuria ratio or increase partial and complete remissions and kidney function was stable in the 2 groups according to estimated glomerular filtration rate and serum creatinine level. Expand
Intravenous cyclophosphamide and oral prednisolone is a safe and effective treatment option for idiopathic membranous nephropathy
Treatment with IV cyclophosphamide and oral prednisolone was associated with a significantly higher number of patients achieving remission, and this regimen was well tolerated, with few significant treatment-associated side effects. Expand
A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy.
A six-month therapy with methylprednisolone and chlorambucil increases the probability of remission of proteinuria and protects from renal function deterioration even in the long-term. Expand
Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.
It is suggested that Rtx might replace St-Cp as first-line immunosuppressive therapy in patients with idiopathic membranous nephropathy and nephrotic syndrome and that Rituximab (Rtx) may be a safer alternative. Expand
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
Rituximab was noninferior to cyclosporine in inducing complete or partial remission of proteinuria at 12 months and was superior in maintaining proteinuria remission up to 24 months. Expand
Rituximab Treatment for Membranous Nephropathy: A French Clinical and Serological Retrospective Study of 28 Patients
In this retrospective study, a high rate of remission was achieved 12 months after treatment of patients treated with rituximab for idiopathic MN, and univariate analysis suggested that the degree of renal failure is an independent factor that predicts lack of response to ritUXimab. Expand
Controlled trial of cyclophosphamide in idiopathic membranous nephropathy.
It is concluded that treatment with cyclophosphamide for one year did not have a favorable effect on proteinuria, renal function or morphologic aspects of the glomerular lesion. Expand